Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

Conclusions: Prior real-world data in ET has predominately been generated outside of the United States or has been reported from single institutional experiences. The MOST study will provide a more complete picture of the patient characteristics and outcomes of patients receiving ET-directed therapy in the United States. Ultimately, these data will be important for determining ET treatment gaps and areas of unmet need.DisclosuresYacoub: Cara Therapeutics: Equity Ownership; Inycte: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Ardelyx, INC.: Equity Ownership; Seattle Genetics: Honoraria, Speakers Bureau; Dynavax: Equity Ownership. Verstovsek: Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Italfarmaco: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy. Shao: ASH: Membership on an entity's Board of Directors or advisory committees; ASCO: Membership on an entity's Board of Directors or advisory committees. Agrawal: Incyte: Speakers Bureau. Sivaraman: Incyte: Employment. Colucci: Incyte: Employment, Equity Ownership. Yao: Incyte: Employment. Mascarenhas: Celgene: Membership on an entity's Board of Directors or advisory committees; Promedior: Research Funding; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Fu...

Source: Blood - November 21, 2018 Category: Hematology Authors: Yacoub, A., Lyons, R. M., Verstovsek, S., Shao, R., Chu, D. T., Agrawal, A., Sivaraman, S., Colucci, P., Yao, P., Mascarenhas, J. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster III Source Type: research